*pharmaceuticals*

MDPI

*Correction*

# Correction: Juhás et al. Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole. *Pharmaceuticals* 2022, *15*, 580

**Martin Juhás [1,*], Andrea Bachtíková [1], Daria Elżbieta Nawrot [1], Paulína Hatoková [1], Vinod Sukanth Kumar Pallabothula [1], Adéla Diepoltová [1], Ondřej Janďourek [1], Pavel Bárta [1], Klára Konečná [1], Pavla Paterová [2], Vít Šesták [3] and Jan Zitko [1,*]**

1 Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
2 Department of Clinical Microbiology, University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Czech Republic
3 Department of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Králové, University Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic
* Correspondence: juhasm@faf.cuni.cz (M.J.); jan.zitko@faf.cuni.cz (J.Z.); Tel.: +420-495-067-272 (M.J.); +420-495-067-409 (J.Z.)

In the original publication [1], there was a mistake in assigning individual compounds to their structural subtype in Figure 2 and Table 1. In correction, subtype I comprises compounds **1–10**, and subtype II comprises compounds **11–20**. Also, for compounds **11–13** in Table 1, we unified the naming of the Ar substituent, using the pyridinyl convention instead of pyridyl (to achieve consistency with the rest of the paper). The corrected Figure 2 and Table 1 appear below. We made the same changes to Table S2 in the Supplementary Material. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the academic editor. The original publication has also been updated.




**Figure 2.** Synthetic procedure used to prepare title compounds. Conditions: **a:** (for X = S) 1.1 eq. urea, in EtOH, reflux 2 h; **b:** (for X = O) 10 eq. urea, in MeCN, reflux 16 h or in DMF, 120 °C 2 h; **c**: 1 eq. acyl chloride, 3 eq. DIPEA or pyridine, in DCM, overnight; **d**: 10 eq. thionyl chloride, catalytic DMF.

check for updates

**Citation:** Juhás, M.; Bachtíková, A.; Nawrot, D.E.; Hatoková, P.; Pallabothula, V.S.K.; Diepoltová, A.; Janďourek, O.; Bárta, P.; Konečná, K.; Paterová, P.; et al. Correction: Juhás et al. Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole. *Pharmaceuticals* 2022, *15*, 580. *Pharmaceuticals* **2023**, *16*, 384. https://doi.org/10.3390/ph16030384

Received: 13 February 2023
Accepted: 21 February 2023
Published: 2 March 2023

**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Table 1.** Structures, log k'$_w$, HepG2 cytotoxicity, and MIC against Mtb H37Ra of the title compounds.

| Structure | Code | Ar | X | log k'w | HepG2 IC50 (μM) | Mtb H37Ra MIC (μg/mL) |
|---|---|---|---|---|---|---|
| **Subtype I**<br>  <br>**1–10**<br>**a**: X = S<br>**b**: X = O | **1a** | pyridin-2-yl | S | 1.857 | >1000 * | 31.25 |
| | **1b** | pyridin-2-yl | O | 0.854 | >1000 * | 62.5 |
| | **2a** | pyridin-3-yl | S | 1.251 | >1000 * | 250 |
| | **2b** | pyridin-3-yl | O | 0.436 | >1000 * | 31.25 |
| | **3a** | pyridin-4-yl | S | 1.306 | >1000 * | 250 |
| | **3b** | pyridin-4-yl | O | 0.396 | >1000 * | 15.625 |
| | **4b** | 5-Me-pyridin-3-yl | O | 0.888 | >1000 * | 7.81 |
| | **5b** | 2-Me-pyridin-4-yl | O | 0.714 | >1000 * | 3.91 |
| | **6a** | 2-Cl-pyridin-4-yl | S | 2.013 | >250 ** | ≥500 |
| | **6b** | 2-Cl-pyridin-4-yl | O | 1.136 | 664.1 | 3.125 |
| | 7a | 2-Cl-6-Me-pyridin-4-yl | S | 2.319 | >250 ** | ≥500 |
| | **7b** | 2-Cl-6-Me-pyridin-4-yl | O | 1.430 | 959.4 | <3.91 |
| | **8a** | pyrazin-2-yl | S | 1.222 | n.d. | 62.5 |
| | **8b** | pyrazin-2-yl | O | 0.154 | n.d. | 31.25 |
| | **9a** | 5-Cl-pyrazin-2-yl | S | 1.941 | n.d. | 31.25 |
| | **9b** | 5-Cl-pyrazin-2-yl | O | 0.958 | n.d. | 31.25 |
| | **10a** | quinoxalin-2-yl | S | 2.530 | >50 ** | ≥250 |
| | **10b** | quinoxalin-2-yl | O | 1.493 | >1000 * | 15.625 |
| **Subtype II**<br>  <br>**11–20**<br>**a**: X = S<br>**b**: X = O | **11a** | pyridin-2-yl | S | 3.102 | >100 ** | 3.91 |
| | **11b** | pyridin-2-yl | O | 2.038 | 883.4 | 3.91 |
| | **12a** | pyridin-3-yl | S | 2.131 | >25 ** | ≥500 |
| | **12b** | pyridin-3-yl | O | 1.118 | 610.3 | 125 |
| | **13a** | pyridin-4-yl | S | 2.190 | >100 ** | 7.81 |
| | **13b** | pyridin-4-yl | O | 1.163 | 879.3 | 31.25 |
| | **14b** | 5-Me-pyridin-3-yl | O | 1.478 | >100 ** | ≥250 |
| | **15a** | 2-Cl-pyridin-4-yl | S | 3.036 | 102.6 | 3.91 |
| | **15b** | 2-Cl-pyridin-4-yl | O | 1.992 | 136.1 | 7.81 |
| | **16a** | 2-Cl-6-Me-pyridin-4-yl | S | 3.314 | n.d. | 7.81 |
| | **16b** | 2-Cl-6-Me-pyridin-4-yl | O | 2.251 | n.d. | 15.625 |
| | **17a** | pyrazin-2-yl | S | 2.365 | n.d. | >50 [11] |
| | **17b** | pyrazin-2-yl | O | 1.306 | >1000 * | 15.625 |
| | **18a** | 5-Cl-pyrazin-2-yl | S | 3.173 | n.d. | >100 [11] |
| | **18b** | 5-Cl-pyrazin-2-yl | O | 2.073 | >100 ** | 15.625 |
| | **19a** | quinoxalin-2-yl | S | 3.583 | n.d. | ≥500 |
| | **19b** | quinoxalin-2-yl | O | 2.465 | n.d. | ≥500 |
| | **20b** | phenyl | O | 2.090 | 330.3 | 62.5 |
| | **CIP** | - | - | - | - | 0.25 |
| | **INH** | - | - | - | - | 0.25 |
| | **RIF** | - | - | - | - | 0.003–0.0015 |

* $IC_{50}$ above the highest tested concentration; ** exact $IC_{50}$ value could not be determined due to insolubility in the testing medium at higher concentrations; CIP—ciprofloxacin; INH—isoniazid; RIF—rifampicin; n.d.—not determined.

## Reference

1. Juhás, M.; Bachtíková, A.; Nawrot, D.E.; Hatoková, P.; Pallabothula, V.S.K.; Diepoltová, A.; Janďourek, O.; Bárta, P.; Konečná, K.; Paterová, P.; et al. Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole. *Pharmaceuticals* **2022**, *15*, 580. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.